1-8 of 8
Min Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma

Available to Purchase
Xinyi Yang, Yuanyuan Liu, Peng Wang, Min Li, Tong Xiang, Songzuo Xie, Minxing Li, Yan Wang, Desheng Weng, Jingjing Zhao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (12): 1731–1742.
https://doi.org/10.1158/1535-7163.MCT-24-0222
Published: 03 December 2024
View articletitled, Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma
Open the PDF for Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide

Free
Luping Huang, Denian Wang, Zhongxue Feng, Huan Zhao, Fei Xiao, Yong'gang Wei, Heng Zhang, Hongyu Li, Lingmiao Kong, Min Li, Fei Liu, Haili Zhang, Wei Zhang
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (2): 284–295.
https://doi.org/10.1158/1535-7163.MCT-20-0619
Published: 05 February 2021
View articletitled, Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide
Open the PDF for Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide in another window
Includes: Supplementary data
Journal Articles

Abstract C067: Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA

Free
Long Gu, Min Li, Robert Lingeman, Robert J Hickey, Yilun Liu, Linda H Malkas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C067.
https://doi.org/10.1158/1535-7163.TARG-19-C067
Published: 01 December 2019
View articletitled, Abstract C067: Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA
Journal Articles

Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma

Free
Kexin Xu, Geng Sun, Min Li, Hongling Chen, Zuhao Zhang, Xixi Qian, Ping Li, Lin Xu, Wenbin Huang, Xuerong Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (11): 2085–2096.
https://doi.org/10.1158/1535-7163.MCT-18-1181
Published: 01 November 2019
View articletitled, Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Open the PDF for Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B071: Detecting ultra low-frequency variants and fusions using a novel amplicon-based Accu-CometTM method

Free
Ling Wang, Grace Q. Zhao, Li Weng, Xiao Chen, Min Li, Xue Yang, Jun Zhao, Hongyan Wang, Kang Ying, Malek Faham, Shengrong Lin, Jiatao Lou
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B071.
https://doi.org/10.1158/1535-7163.TARG-17-B071
Published: 01 January 2018
View articletitled, Abstract B071: Detecting ultra low-frequency variants and fusions using a novel amplicon-based Accu-CometTM method
Journal Articles

Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.

Free
Katharine C. Lai, Hans K. Erickson, Xiuxia Sun, Peter U. Park, Jutta Deckert, Min Li, Yong Yi, Jan Pinkas, Jennifer A. Coccia, Sara Nadworny
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B209.
https://doi.org/10.1158/1535-7163.TARG-11-B209
Published: 12 November 2011
View articletitled, Abstract B209: The CD37-targeting ADC IMGN529 combines the potent anticancer activity of K7153A antibody with efficient maytansinoid delivery.
Journal Articles

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Free
Min Li, Uddalak Bharadwaj, Rongxin Zhang, Sheng Zhang, Hong Mu, William E. Fisher, F. Charles Brunicardi, Changyi Chen, Qizhi Yao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (2): 286–296.
https://doi.org/10.1158/1535-7163.MCT-07-0483
Published: 15 February 2008
View articletitled, Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
Open the PDF for Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer in another window
Includes: Supplementary data
Journal Articles

Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival

Free
Rubén W. Carón, Adly Yacoub, Min Li, Xiaoyu Zhu, Clint Mitchell, Young Hong, William Hawkins, Takehiko Sasazuki, Senji Shirasawa, Alan P. Kozikowski, Philip A. Dennis, Michael P. Hagan, Steven Grant, Paul Dent
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (2): 257–270.
https://doi.org/10.1158/1535-7163.257.4.2
Published: 15 February 2005
View articletitled, Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival
Open the PDF for Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival in another window